What does the World Health Organization say about CBD?
According to assessments by the World Health Organization (WHO), the substance cannabidiol (CBD) is considered a safe active ingredient. Corresponding legalizations could therefore take place soon.
Autor
Philip Schmiedhofer, MSc
Inhaltsverzeichnis
WHO SAFETY PROFILE ON CBD
The expert committee report on drug dependence published by the WHO in November 2017 states that the ingredient cannabidiol has good tolerability.
The expert committee report on drug dependence published by the WHO in November 2017 states that the ingredient cannabidiol has good tolerability—provided a good safety profile exists. Scientific findings were used for the analysis to provide an assessment of the therapeutic qualities as well as side effects of CBD. Based on these, it was determined whether cannabis should be subject to international controls as a medicinal product in the future. Test results in both animals and humans concluded that CBD is generally well tolerated. The medical treatment of CBD in epilepsy patients has been the most extensively researched so far. According to the WHO, however, there is also the possibility of helping other patients with various diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, and diabetes with cannabis-based medicines.
The published committee report states that cannabidiol, unlike the active ingredient THC (tetrahydrocannabinol), does not cause dependency, psychoactive effects, or any negative impacts on anxiety, heart rate, or even high blood pressure.International bans on pure cannabidiol therefore do not seem justified.
The complete WHO report can be read in full on the following page:
Philip is the CEO and co-founder of cannhelp GmbH. With a degree in medical engineering and molecular biology, specializing in neuroscience and focusing on cannabinoids, he is recognized as an expert in the medical application of cannabinoids. As a medical device consultant, he also leads the sales of cannmedic and provides specialized advice to medical professionals. His expertise includes the development and sales of cannabinoid-based products. In research, he participates in significant basic research at the Center for Brain Research at the Medical University of Vienna. As co-founder and current CEO of cannmedic GmbH, a pioneer in the CBD medical products market, he has many years of entrepreneurial experience. Additionally, he maintains an extensive network in the industry and advises internationally operating companies in the field of medical cannabinoids.
Use the left/right arrows to navigate through the slideshow, or swipe left or right if you are using a mobile device.
When you select an option, a full page will be refreshed.
Press the spacebar and then the arrow keys to make a selection.
